# Pipe-307 dose a PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pipe-307

> Pipe-307 dose a, sponsored by JOHNSON & JOHNSON (JNJ): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pipe-307 dose a |
| Codes | PIPE-307, JNJ-5120 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [relapsing-remitting multiple sclerosis](https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis), rrms, referred to, [Relapsing Remitting Multiple Sclerosis](https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: RRMS, referred to.
- First seen 2025-03-06, last confirmed 2025-03-06.
- SEC Form 10-K (accession 0001437749-25-006458): "In November 2023, we initiated a Phase 2 randomized, double-blind, placebo-controlled, dose-ranging multi-center trial to evaluate the safety and efficacy of oral PIPE-307 as an adjunctive treatment in subjects with RRMS, referred to as the VISTA trial." https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-08-05, last confirmed 2025-08-05.
- SEC Form 10-Q (accession 0001437749-25-024852): "We completed enrollment of our Phase 2 clinical trial in December 2024, and expect the topline data from this trial will be available in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925024852/ctnm20250630_10q.htm

### July 14, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsing Remitting Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06083753 (Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06083753

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: relapsing-remitting multiple sclerosis.
- First seen 2025-03-06, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-032422): "- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ex_870706.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-032422): "The Company expects to report topline data from its ongoing PIPE-307 Phase 2 VISTA RRMS trial in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ex_870706.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-024849): "- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ex_831554.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-024849): "The Company expects to report topline data from its ongoing PIPE-307 Phase 2 VISTA relapsing-remitting multiple sclerosis (RRMS) trial in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ex_831554.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-024849): "We also expect to report topline data from our PIPE-307 Phase 2 VISTA trial for the treatment of RRMS in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ex_831554.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-016877): "- Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) anticipated in the second half of 2025" https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/ex_793225.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-016877): "Contineum expects topline data from its PIPE-307 Phase 2 VISTA RRMS trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/ex_793225.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-006457): "- Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) anticipated in the second half of 2025" https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/ex_778773.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-006457): "Contineum expects topline data from its PIPE-307 Phase 2 VISTA RRMS trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/ex_778773.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-032422): ""First, we expect to report topline data from our PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) before the end of the year." https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ex_870706.htm
- SEC Form 10-Q (accession 0001437749-25-032427): "We completed enrollment of our Phase 2 clinical trial in December 2024, and expect the topline data from this trial will be available in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925032427/ctnm20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-016835): "We completed enrollment of our Phase 2 clinical trial in December 2024, and expect the top-line data from this trial will be available in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1855175/000143774925016835/cont20250331_10q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pipe-307.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pipe-307 dose a PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pipe-307

```bibtex
@misc{secapidev_pdufa_pipe_307_20261116,
  title        = {Pipe-307 dose a PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pipe-307}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pipe_307_20261116","title":"Pipe-307 dose a PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pipe-307","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
